Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Court Decision Means Longer Wait For Clarity On EMA’s Access To Documents Policy

Executive Summary

The EU court’s dismissal of appeals filed by the European Medicines Agency in cases relating to its access to documents policy means stakeholders will have to wait even longer to get legal clarity on the policy. One lawyer believes that the case could result in a broader definition of what constitutes commercially confidential information.

You may also be interested in...



Pharma Opposes 'Harmful' Changes To EMA’s Access To Documents Policy

The EU pharmaceutical industry has concerns about the European Medicines Agency’s proposal to grant extended access to documents on orphan designations and pediatric investigation plans under its revised access to documents policy. The changes would discourage innovation and lead to inadvertent disclosure of commercially sensitive data, companies claim.

It’s Started: EMA Proactively Publishes Clinical Data On New Drugs

The European Medicines Agency has delivered on its promise to grant public access to clinical reports that form the basis of its recommendations to the European Commission on whether or not a medicine should be authorized for use in the EU.

EMA Appeals Interim EU Court Orders Preventing Access To Documents

The European Medicines Agency is looking for a clear indication from the EU courts on whether its approach to transparency – as defined in its access to documents policy – is correct.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel